Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa | Zendy

Jonathan D. Edgeworth | Zendy; Domenico Merante | Zendy; Sanjay Patel | Zendy; Christopher Young | Zendy; Paul Jones | Zendy; Seema Vithlani | Zendy; Duncan Wyncoll | Zendy; Peter Roberts | Zendy; Andrew Jones | Zendy; Tsutae Den Nagata | Zendy; Mari Ariyasu | Zendy; David M. Livermore | Zendy; Richard Beale | Zendy

Open Access

Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa

Author(s) -

Jonathan D. Edgeworth,

Domenico Merante,

Sanjay Patel,

Christopher Young,

Paul Jones,

Seema Vithlani,

Duncan Wyncoll,

Peter Roberts,

Andrew Jones,

Tsutae Den Nagata,

Mari Ariyasu,

David M. Livermore,

Richard Beale

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy963

Subject(s) - pseudomonas aeruginosa , endocarditis , medicine , colistin , adjunctive treatment , aortic valve , drug , bacteremia , microbiology and biotechnology , intensive care medicine , antibiotics , bacteria , pharmacology , biology , genetics

Serious infections such as endocarditis due to extremely drug-resistance gram-negative bacteria are an increasing challenge. Here, we present successful adjunctive use of cefiderocol for a patient with persistently bacteremic healthcare-associated native aortic valve endocarditis due to an extended-spectrum beta-lactamase-positive Pseudomonas aeruginosa susceptible in vitro only to colistin, following failure of conventional therapeutic options.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research